Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Breast Cancer Research and Treatment
Published in: Breast Cancer Research and Treatment 3/2018

01-06-2018 | Epidemiology

Differences in breast cancer incidence among young women aged 20–49 years by stage and tumor characteristics, age, race, and ethnicity, 2004–2013

Authors: Meredith L. Shoemaker, Mary C. White, Manxia Wu, Hannah K. Weir, Isabelle Romieu

Published in: Breast Cancer Research and Treatment | Issue 3/2018

Login to get access

Abstract

Purpose

Younger women diagnosed with breast cancer have poorer prognoses and higher mortality compared to older women. Young black women have higher incidence rates of breast cancer and more aggressive subtypes than women of other races/ethnicities. In this study, we examined recent trends and variations in breast cancer incidence among young women in the United States.

Methods

Using 2004–2013 National Program of Cancer Registries and Surveillance, Epidemiology, and End Results Program data, we calculated breast cancer incidence rates and trends and examined variations in stage, grade, and tumor subtype by age and race/ethnicity among young women aged 20–49 years.

Results

The majority of breast cancer cases occurred in women aged 40–44 and 45–49 years (77.3%). Among women aged < 45 years, breast cancer incidence was highest among black women. Incidence trends increased from 2004 to 2013 for Asian or Pacific Islander (API) women and white women aged 20–34 years. Black, American Indian or Alaska Native, and Hispanic women had higher proportions of cases diagnosed at later stages than white and API women. Black women had a higher proportion of grade III–IV tumors than other racial/ethnic groups. Across all age groups, incidence rates for triple-negative breast cancer were significantly higher in black women than women of other races/ethnicities, and this disparity increased with age.

Conclusions

Breast cancer among young women is a highly heterogeneous disease. Differences in tumor characteristics by age and race/ethnicity suggest opportunities for further research into personal and cultural factors that may influence breast cancer risk among younger women.
Literature
1.
Assi HA, Khoury KE, Dbouk H, Khalil LE, Mouhieddine TH, El Saghir NS (2013) Epidemiology and prognosis of breast cancer in young women. J Thorac Dis 5(Suppl 1):S2–S8PubMedPubMedCentral
2.
3.
Warner ET, Colditz GA, Palmer JR, Partridge AH, Rosner BA, Tamimi RM (2013) Reproductive factors and risk of premenopausal breast cancer by age at diagnosis: are there differences before and after age 40? Breast Cancer Res Treat 142(1):165–175CrossRefPubMed
4.
Chollet-Hinton L, Anders CK, Tse C-K, Bell MB, Yang YC, Carey LA, Olshan AF, Troester MA (2016) Breast cancer biologic and etiologic heterogeneity by young age and menopausal status in the Carolina Breast Cancer Study: a case-control study. Breast Cancer Res 18(79):5
5.
Chen HL, Zhou MQ, Tian W, Meng KX, He HF (2016) Effect of age on breast cancer patient prognoses: a population-based study using the SEER 18 database. PLoS ONE 11(10):e0165409CrossRefPubMedPubMedCentral
6.
7.
Ekwueme DU, Trogdon JG, Khavjou OA, Guy GP Jr (2016) Productivity costs associated with breast cancer among survivors aged 18–44 years. Am J Prev Med 50(2):286–294CrossRefPubMed
8.
Ekwueme DU, Allaire BT, Guy GP Jr, Arnold S, Trogdon JG (2016) Treatment costs of breast cancer among younger women aged 19–44 years enrolled in Medicaid. Am J Prev Med 50(2):278–285CrossRefPubMedPubMedCentral
9.
Allaire BT, Ekwueme DU, Guy GP Jr, Li C, Tangka FK, Trivers KF, Sabatino SA, Rodriguez JL, Trogdon JG (2016) Medical care costs of breast cancer in privately insured women aged 18–44 years. Am J Prev Med 50(2):270–277CrossRefPubMedPubMedCentral
10.
Richardson LC, Henley SJ, Miller JW, Massetti G, Thomas CC (2016) Patterns and trends in age-specific black-white differences in breast cancer incidence and mortality—United States, 1999–2014. MMWR Morb Mortal Wkly Rep 65(40):1093–1098CrossRefPubMed
11.
Brinton LA, Sherman ME, Carreon JD, Anderson WF (2008) Recent trends in breast cancer among younger women in the United States. J Natl Cancer Inst 100(22):1643–1648CrossRefPubMedPubMedCentral
12.
Johnson RH, Chien FL, Bleyer A (2013) Incidence of breast cancer with distant involvement among women in the United States, 1976 to 2009. JAMA 309(8):800–805CrossRefPubMed
13.
DeSantis CE, Fedewa SA, Goding Sauer A, Kramer JL, Smith RA, Jemal A (2016) Breast cancer statistics, 2015: convergence of incidence rates between black and white women. CA Cancer J Clin 66(1):31–42CrossRefPubMed
14.
White MC, Espey DK, Swan J, Wiggins CL, Eheman C, Kaur JS (2014) Disparities in cancer mortality and incidence among American Indians and Alaska Natives in the United States. Am J Public Health 104(Suppl 3):S377–S387CrossRefPubMedPubMedCentral
15.
Newman LA (2014) Breast cancer disparities: high-risk breast cancer and African ancestry. Surg Oncol Clin N Am 23(3):579–592CrossRefPubMed
16.
Dunn BK, Agurs-Collins T, Browne D, Lubet R, Johnson KA (2010) Health disparities in breast cancer: biology meets socioeconomic status. Breast Cancer Res Treat 121(2):281–292CrossRefPubMed
17.
Williams DR, Mohammed SA, Shields AE (2016) Understanding and effectively addressing breast cancer in African American women: Unpacking the social context. Cancer 122(14):2138–2149CrossRefPubMedPubMedCentral
18.
Miller JW, Lee Smith J, Ryerson BA, Tucker TC, Allemani C (2017) Disparities in breast cancer survival in the United States (2001–2009): findings from the CONCORD-2 study. Cancer 123(S24):5100–5118CrossRefPubMed
19.
Thornton ML (ed) (2014) Standards for cancer registries Volume II: data standards and data dictionary, record layout version 15, 19th ed., North American Association of Central Cancer Registries. Springfield, IL
20.
National Program of Cancer Registries and Surveillance Epidemiology & End Results (2016) NPCR and SEER incidence—USCS 2001–2014 public use database data standards and data dictionary, vol. 2017
21.
22.
Young JL Jr RS, Ries LAG, Fritz AG, Hurlbut AA (2001) SEER summary staging manual—2000: codes and coding instructions, National Cancer Institute. In: NIH Pub No 01-4969. Bethesda, MD
23.
Surveillance Research Program National Cancer Institute: SEER*Stat software (seer.cancer.gov/seerstat) version 8.3.4
24.
Gomez SL, Von Behren J, McKinley M, Clarke CA, Shariff-Marco S, Cheng I, Reynolds P, Glaser SL (2017) Breast cancer in Asian Americans in California, 1988–2013: increasing incidence trends and recent data on breast cancer subtypes. Breast Cancer Res Treat 164(1):139–147CrossRefPubMedPubMedCentral
25.
Kohler BA, Sherman RL, Howlader N, Jemal A, Ryerson AB, Henry KA, Boscoe FP, Cronin KA, Lake A, Noone A-M et al (2015) Annual Report to the Nation on the Status of Cancer, 1975–2011, featuring incidence of breast cancer subtypes by race/ethnicity, poverty, and state. J Natl Cancer Inst 107(6):djv048CrossRefPubMedPubMedCentral
26.
Keegan THM, DeRouen MC, Press DJ, Kurian AW, Clarke CA (2013) Occurrence of breast cancer subtypes in adolescent and young adult women. Breast Cancer Res 15(5):R95CrossRefPubMedPubMedCentral
27.
Horne HN, Beena Devi CR, Sung H, Tang TS, Rosenberg PS, Hewitt SM, Sherman ME, Anderson WF, Yang XR (2015) Greater absolute risk for all subtypes of breast cancer in the US than Malaysia. Breast Cancer Res Treat 149(1):285–291CrossRefPubMed
28.
Ambrosone CB, Zirpoli G, Ruszczyk M, Shankar J, Hong CC, McIlwain D, Roberts M, Yao S, McCann SE, Ciupak G et al (2014) Parity and breastfeeding among African-American women: differential effects on breast cancer risk by estrogen receptor status in the Women’s Circle of Health Study. Cancer Causes Control 25(2):259–265CrossRefPubMed
29.
Boyle P (2012) Triple-negative breast cancer: epidemiological considerations and recommendations. Ann Oncol 23(Suppl 6):vi7–vi12CrossRefPubMed
30.
Anstey EH, Shoemaker ML, Barrera CM, O’Neil ME, Verma AB, Holman DM (2017) Breastfeeding and breast cancer risk reduction. Implications for black mothers. Am J Prev Med 53(3s1):S40–S46CrossRefPubMedPubMedCentral
31.
Trivers KF, Lund MJ, Porter PL, Liff JM, Flagg EW, Coates RJ, Eley JW (2009) The epidemiology of triple-negative breast cancer, including race. Cancer Causes Control 20(7):1071–1082CrossRefPubMedPubMedCentral
32.
Brewster AM, Chavez-MacGregor M, Brown P (2014) Epidemiology, biology, and treatment of triple-negative breast cancer in women of African ancestry. Lancet Oncol 15(13):e625–e634CrossRefPubMedPubMedCentral
33.
Shavers VL, Harlan LC, Stevens JL (2003) Racial/ethnic variation in clinical presentation, treatment, and survival among breast cancer patients under age 35. Cancer 97(1):134–147CrossRefPubMed
34.
Ademuyiwa FO, Gao F, Hao L, Morgensztern D, Aft RL, Ma CX, Ellis MJ (2015) US breast cancer mortality trends in young women according to race. Cancer 121(9):1469–1476CrossRefPubMed
35.
Amirikia KC, Mills P, Bush J, Newman LA (2011) Higher population-based incidence rates of triple-negative breast cancer among young African-American women: implications for breast cancer screening recommendations. Cancer 117(12):2747–2753CrossRefPubMedPubMedCentral
36.
Liu P, Li X, Mittendorf EA, Li J, Du XL, He J, Ren Y, Yang J, Hunt KK, Yi M (2013) Comparison of clinicopathologic features and survival in young American women aged 18-39 years in different ethnic groups with breast cancer. Br J Cancer 109(5):1302–1309CrossRefPubMedPubMedCentral
37.
Ooi SL, Martinez ME, Li CI (2011) Disparities in breast cancer characteristics and outcomes by race/ethnicity. Breast Cancer Res Treat 127(3):729–738CrossRefPubMed
38.
Howlader N, Altekruse SF, Li CI, Chen VW, Clarke CA, Ries LAG, Cronin KA (2014) US incidence of breast cancer subtypes defined by joint hormone receptor and HER2 status. J Natl Cancer Inst 106(5):dju055CrossRefPubMedPubMedCentral
39.
Parise CA, Bauer KR, Caggiano V (2010) Variation in breast cancer subtypes with age and race/ethnicity. Crit Rev Oncol Hematol 76(1):44–52CrossRefPubMed
40.
Oeffinger KC, Fontham EH, Etzioni R et al (2015) Breast cancer screening for women at average risk: 2015 guideline update from the American Cancer Society. JAMA 314(15):1599–1614CrossRefPubMedPubMedCentral
41.
42.
American College of Obstetricians and Gynecologists (2011) Practice bulletin no. 122: breast cancer screening. Obstet Gynecol 118(2 Pt 1):372–382
43.
Hale PJ, Gilson deValpine M (2014) Screening mammography: revisiting assumptions about early detection. The Journal for Nurse Practitioners 10(3):183–188CrossRef
44.
International Agency for Research on Cancer (2015) IARC handbooks of cancer prevention, vol 15. Breast Cancer Screening, Lyon
45.
46.
Ruddy KJ, Gelber S, Tamimi RM, Schapira L, Come SE, Meyer ME, Winer EP, Partridge AH (2014) Breast cancer presentation and diagnostic delays in young women. Cancer 120(1):20–25CrossRefPubMed
47.
48.
Malone KE, Daling JR, Neal C, Suter NM, O’Brien C, Cushing-Haugen K, Jonasdottir TJ, Thompson JD, Ostrander EA (2000) Frequency of BRCA1/BRCA2 mutations in a population-based sample of young breast carcinoma cases. Cancer 88(6):1393–1402CrossRefPubMed
49.
Greenup R, Buchanan A, Lorizio W, Rhoads K, Chan S, Leedom T, King R, McLennan J, Crawford B, Kelly Marcom P et al (2013) Prevalence of BRCA mutations among women with triple-negative breast cancer (TNBC) in a genetic counseling cohort. Ann Surg Oncol 20(10):3254–3258CrossRefPubMed
50.
Anderson KN, Schwab RB, Martinez ME (2014) Reproductive risk factors and breast cancer subtypes: a review of the literature. Breast Cancer Res Treat 144(1):1–10CrossRefPubMedPubMedCentral
51.
52.
Institute of Medicine (2012) Breast cancer and the environment: a life course approach. The National Academies Press, Washington, DC
53.
Ekwueme DU, Allaire BT, Parish WJ, Thomas CC, Poehler D, Guy GP Jr, Aldridge AP, Lahoti SR, Fairley TL, Trogdon JG (2017) Estimation of breast cancer incident cases and medical care costs attributable to alcohol consumption among insured women aged < 45 years in the U.S. Am J Prev Med 53(3s1):S47–S54CrossRefPubMedPubMedCentral
54.
White MC, Shoemaker ML, Park S, Neff LJ, Carlson SA, Brown DR, Kanny D (2017) Prevalence of modifiable cancer risk factors among U.S. adults aged 18–44 years. Am J Prev Med 53(3s1):S14–S20CrossRefPubMedPubMedCentral
55.
Fredholm H, Eaker S, Frisell J, Holmberg L, Fredriksson I, Lindman H (2009) Breast cancer in young women: poor survival despite intensive treatment. PLoS ONE 4(11):e7695CrossRefPubMedPubMedCentral
56.
57.
Metadata
Title
Differences in breast cancer incidence among young women aged 20–49 years by stage and tumor characteristics, age, race, and ethnicity, 2004–2013
Authors
Meredith L. Shoemaker
Mary C. White
Manxia Wu
Hannah K. Weir
Isabelle Romieu
Publication date
01-06-2018
Publisher
Springer US
Published in
Breast Cancer Research and Treatment / Issue 3/2018
Print ISSN: 0167-6806
Electronic ISSN: 1573-7217
DOI
https://doi.org/10.1007/s10549-018-4699-9

Other articles of this Issue 3/2018

Breast Cancer Research and Treatment 3/2018 Go to the issue

Epidemiology

Physical activity during adolescence and young adulthood and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers

Clinical trial

Evaluation of [89Zr]trastuzumab-PET/CT in differentiating HER2-positive from HER2-negative breast cancer

Clinical trial

Performance of breast cancer screening using digital breast tomosynthesis: results from the prospective population-based Oslo Tomosynthesis Screening Trial

Clinical trial

Patient-reported predictors of early treatment discontinuation: treatment-related symptoms and health-related quality of life among postmenopausal women with primary breast cancer randomized to anastrozole or exemestane on NCIC Clinical Trials Group (CCTG) MA.27 (E1Z03)

Clinical trial

Acute toxicity of intraoperative radiotherapy and external beam-accelerated partial breast irradiation in elderly breast cancer patients

Clinical trial

Do patients whose tumor achieved a pathological response relapse at specific sites? A substudy of the EORTC 10994/BIG-1-00 trial
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits